Evidence map›Paper›PMID 36522588›Full record

ArticleInternational journal of hematology2023

The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.

He Li, Ting Niu, Jie Huang, Liping Xie, Chuan He, Jianjun Li, Bing Xiang, Xu Cui, Yu Wu, Yun Tang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

He LiDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Ting NiuDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Jie HuangDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Liping XieDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Chuan HeDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Jianjun LiDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Bing XiangDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Xu CuiDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Yu WuDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Yun TangDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Yongqian JiaDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Zhigang LiuDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China.
Hongbing MaDepartment of Hematology, Institute of Hematology, West China Hospital of Sichuan University, #37 Guo Xue Xiang Street, Chengdu, 610041, Sichuan, China. hongbingma@foxmail.com.ORCID http://orcid.org/0000-0002-1174-4078
Sichuan University · CN

Funding

1·3·5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University 2022HXFH040
6 · The paper itself

Abstract

Intracranial hemorrhage (ICH) is a major cause of early death (ED) and leads to poor prognosis in acute promyelocytic leukemia (APL). We retrospectively described 27 unselected APL patients who experienced early ICH. The ED rate was 37%. The 3-year overall survival (OS) rate was 45.4%, while the 3-year OS rate of patients who survived through induction therapy was 87.5%. No patient experienced central nervous system leukemia (CNSL). Concurrent differentiation syndrome, white blood cell count, prothrombin time and D-dimer were related to death. Although the ED rate among APL patients with early ICH was high, patients with early ICH had a favorable outcome after surviving through induction therapy. CNSL was rare despite a history of ICH during induction therapy. Compared with APL patients without ICH, it seems unnecessary to administer additional measures to prevent CNSL for this subpopulation in the era of all-trans retinoic acid and arsenic trioxide, but this needs further validation in prospective trials.

Indexed as

Leukemia, Promyelocytic, AcuteAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideHumansIntracranial HemorrhagesProspective StudiesRetrospective StudiesTretinoinArsenic TrioxideTretinoinAcute promyelocytic leukemiaCentral nervous system leukemiaDifferentiation syndromeEarly deathIntracranial hemorrhage

Identifiers

PMID36522588
OpenAlexW4311669648

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.